JAK Mutations as Escape Mechanisms to Anti-PD-1 Therapy

Cancer Discov. 2017 Feb;7(2):128-130. doi: 10.1158/2159-8290.CD-16-1439.

Abstract

JAK mutations could be one of the primary escape mechanisms to anti-PD-1/PD-L1 immunotherapy via impaired IFNγ signaling in cancer cells and could be used to identify patients unlikely to benefit from these treatments. Cancer Discov; 7(2); 128-30. ©2017 AACR.See related article by Shin et al., p. 188.

Publication types

  • Comment

MeSH terms

  • B7-H1 Antigen / genetics*
  • Humans
  • Immunotherapy
  • Janus Kinase 1
  • Mutation
  • Programmed Cell Death 1 Receptor*

Substances

  • B7-H1 Antigen
  • Programmed Cell Death 1 Receptor
  • JAK1 protein, human
  • Janus Kinase 1